BIO.B vs. VLTO, FTV, TER, RVTY, AVTR, NVMI, VNT, RAL, MIR, and ST
Should you be buying Bio-Rad Laboratories stock or one of its competitors? The main competitors of Bio-Rad Laboratories include Veralto (VLTO), Fortive (FTV), Teradyne (TER), Revvity (RVTY), Avantor (AVTR), Nova (NVMI), Vontier (VNT), Ralliant (RAL), Mirion Technologies (MIR), and Sensata Technologies (ST). These companies are all part of the "measuring and control equipment" industry.
Bio-Rad Laboratories vs. Its Competitors
Veralto (NYSE:VLTO) and Bio-Rad Laboratories (NYSE:BIO.B) are both measuring and control equipment companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.
Veralto has a net margin of 16.56% compared to Bio-Rad Laboratories' net margin of -85.16%. Veralto's return on equity of 45.63% beat Bio-Rad Laboratories' return on equity.
Veralto has higher revenue and earnings than Bio-Rad Laboratories. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Veralto, indicating that it is currently the more affordable of the two stocks.
91.3% of Veralto shares are held by institutional investors. Comparatively, 0.0% of Bio-Rad Laboratories shares are held by institutional investors. 0.4% of Veralto shares are held by company insiders. Comparatively, 28.4% of Bio-Rad Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, Veralto had 13 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 13 mentions for Veralto and 0 mentions for Bio-Rad Laboratories. Veralto's average media sentiment score of 1.49 beat Bio-Rad Laboratories' score of 0.00 indicating that Veralto is being referred to more favorably in the media.
Veralto currently has a consensus price target of $110.09, suggesting a potential upside of 6.89%. Given Veralto's stronger consensus rating and higher probable upside, equities analysts clearly believe Veralto is more favorable than Bio-Rad Laboratories.
Veralto has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500.
Summary
Veralto beats Bio-Rad Laboratories on 15 of the 16 factors compared between the two stocks.
Get Bio-Rad Laboratories News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIO.B and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BIO.B and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BIO.B vs. The Competition
Bio-Rad Laboratories Competitors List
Related Companies and Tools
This page (NYSE:BIO.B) was last updated on 7/18/2025 by MarketBeat.com Staff
